In a phase 1 trial of Fisogatinib, a type 1 irreversible inhibitor of FGFR4, an overall response rate (ORR) of 17% and median duration of response (DOR) of 5.3 months were achieved in patients with hepatocellular carcinoma [34]. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.